CinCor Pharma, Inc. Stock: price and management transactions · United States · SEC (Form 4)

About CinCor Pharma, Inc.

CinCor Pharma, Inc. (ticker: CINC) was a U.S.-based clinical-stage biopharmaceutical company listed on NASDAQ in the United States. For French-speaking investors, it fits squarely within the healthcare/pharma sector, with a specific focus on cardiorenal disease and hypertension. The company was incorporated in March 2018 as a subsidiary of CinRx Pharma and was spun out as an independent company in May 2019. Its principal operations were based in Waltham, Massachusetts, a well-known biopharmaceutical cluster in the U.S. Northeast. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1868734/000095017022004307/cinc-20211231.htm?utm_source=openai)) CinCor’s business model was built around clinical development rather than commercial sales. Its lead asset was baxdrostat, also referred to as CIN-107, an oral, highly selective aldosterone synthase inhibitor. The therapeutic strategy targeted resistant and uncontrolled hypertension, with additional exploration in cardiorenal settings such as chronic kidney disease. As reflected in its SEC filings, CinCor had not commercialized any product, which meant the company was still reliant on external capital and clinical milestones to create shareholder value. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1868734/000095017022004307/cinc-20211231.htm?utm_source=openai)) From a competitive standpoint, CinCor operated in a highly crowded and scientifically demanding biotech niche. Success depended on the strength of clinical data, differentiation of the mechanism of action, and the likelihood of regulatory approval. Baxdrostat’s appeal was its mechanistic positioning in a major unmet-need market: hypertension remains a very large therapeutic area, but patients with resistant or poorly controlled blood pressure are difficult to treat effectively with existing options. That made CinCor’s investment case highly binary, with substantial upside if the program advanced successfully and significant downside if clinical or regulatory execution faltered. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1868734/000095017022008738/cinc-ex99_1.htm?utm_source=openai)) The most important recent development was CinCor’s acquisition by AstraZeneca. In January 2023, the company announced a definitive merger agreement under which AstraZeneca would acquire CinCor, including a cash consideration and a contingent value right tied to certain baxdrostat development milestones. Subsequent SEC materials indicate the transaction closed in February 2023, meaning CINC should no longer be viewed as a standalone publicly traded biotech in the current market context. Form 4 filings around the transaction also show ownership changes consistent with the takeover process. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1868734/000119312523004258/d309038dex991.htm?utm_source=openai)) In summary, CinCor Pharma was a classic single-asset U.S. biotech story: founded in 2018, headquartered in Waltham, Massachusetts, listed on NASDAQ in the United States, and acquired in 2023 after building investor interest around baxdrostat. For investors, it is best understood as a former public cardiorenal development company whose key value-creation event was its absorption into AstraZeneca rather than the emergence of a mature commercial franchise.